About us
Our mission
Since 2021 our mission has been to unlock insights that have a significant strategic impact on life science organizations and improve patient outcomes.
Our industry-leading medical intelligence platform transforms complex scientific data into actionable insights, enabling life science teams to drive change quickly and effectively at scale.
Our unique AI-driven + Human-in-the-Loop approach ensures outstanding accuracy and speed, setting a new benchmark in the generation of healthcare insights while upholding the highest quality standards.
Meet our senior leaders
Tom Hughes leads Virtual Science AI Ltd with a vision to become the world’s leading provider of virtual engagement and insight management services in life sciences. His expertise lies in developing software-as-a-service (SaaS) businesses, with a focus on establishing global organizational infrastructure and adeptly managing P&L responsibilities.
Before founding Virtual Science AI Ltd, Tom was Global Franchise Lead at Pharmaspectra, where he held key commercial leadership positions and drove company growth from 2019 to 2021. Tom began his career as a medical representative in the UK including seven years at Pfizer. There, he progressed through sales and marketing roles, leading teams and managing brands across multiple therapeutic areas. He also led a global initiative at Pfizer to transform virtual selling practices worldwide.
Tom holds a Master of Business Administration (MBA) from the University of Liverpool, United Kingdom.
Chih Han (Hans) Chen is an experienced technology and AI leader focused on empowering life science teams. As a certified data scientist and project leader, he has built multiple successful AI/ML products.
Hans leads a X-strong technology team at Virtual Science AI, applying state-of-the-art technology to deliver actionable intelligence solutions to life sciences organizations.
Prior to joining VSAI, Hans held senior Machine Learning Engineer roles at DNAnudge and Circadia Health.
Hans hold a PhD from Imperial College London.
Chief Technology Officer
As Virtual Science AI’s Chief Customer Officer, Geraldine Reilly oversees and nurtures the company’s growing customer relationships.
Prior to Virtual Science, Geraldine spent 20 years at Gilead Sciences in medical affairs, rising to Executive Medical Affairs Director and later Global Patient Engagement Executive Director. During her tenure at Gilead, she made significant contributions to global medical affairs, developing award-winning medical education programs, building strategic partnerships with Key Opinion Leaders (KOLs), and leading strategy and operations. Geraldine also established and led the global patient engagement team, which focused on integrating patient voices throughout the organization. Throughout her career, she has maintained an active research presence with numerous publications.
Geraldine serves as an elected member of Patient Focused Medicine Development (PFMD) and collaborates closely with PFMD and various patient organizations. With registrations as a General Nurse, District Nurse, and HIV Specialist Nurse, she brings over 25 years of experience in healthcare and the life science industry.
With a strong background in financial leadership and M&A, Udi is passionate about helping companies achieve their full potential. His experience spans both organic scaling and strategic acquisitions, enabling him to navigate growth complexities across diverse situations.
Most recently, as Financial Director at Roboyo, an intelligent automation company, Udi played a pivotal role in scaling the organization from a small team to a global workforce of 500 employees. Prior to Roboyo, Udi worked in investment banking M&A, focusing on the healthcare technology sector. He managed various investment processes that generated significant value for both client businesses and target company shareholders. These transactions served as critical inflection points, strategically positioning companies for their next growth phase.
Udi holds a Chartered Accountant designation and has a strong academic foundation with a degree in Economics and Mathematics from the University of Pennsylvania and additional studies at Imperial College.
Chief Financial Officer
A proven leader with an exceptional blend of technical, business, and commercial expertise, Jason excels at launching businesses, optimizing resources, executing strategic plans, and transforming teams to deliver innovative solutions globally.
As a visionary technologist, Jason consistently creates cutting-edge solutions that both establish new markets and disrupt existing ones. Known for his energy, passion, and tenacity, Jason has established himself as a world leader in the Cyber Security industry, demonstrating excellence in driving transformational change and achieving strategic visions. His straightforward leadership style simplifies complex business decisions and sophisticated technology, while empowering teams to deliver outstanding results.
Jason has built strong relationships across organizations at all levels, securing engagement and buy-in from stakeholders. His deep technical knowledge spans all cybersecurity domains, and he played a key role in establishing the CSO (Chief Security Officer) role as a former ethical hacker.
Technology Advisor
Andrew is Virtual Science AI’s Global Marketing Lead, helping drive brand awareness, customer acquisition, and revenue growth.
Andrew has worked in the pharmaceutical industry for over 30 years, holding various senior commercial positions. Starting at Glaxo in Sales, he quickly moved into Market Access before managing primary and secondary care sales teams. During this period, he worked across multiple therapeutic areas including Respiratory, Gastro, Dermatology, Antibiotics, Diabetes, Oncology, Mental Health, and Neurology.
In 2004, Andrew joined the then-small biotech startup Gilead Sciences, where he would remain for over 18 years. He progressed from National Sales Manager to Marketing Director for the HIV franchise in the UK & Ireland, before taking on strategic planning roles within Gilead’s global organization. In this capacity, he helped over 80 countries worldwide with product launches and lifecycle management, focusing on market mapping, brand campaigns, selling strategies, and pricing.
In 2017, Andrew became Business Unit Director for Liver Disease and Emerging Viruses for the UK & Ireland, managing a $200m portfolio. This role included overseeing an innovative five-year agreement with NHS England to supply drugs and patient-finding services. In 2020, he led commercial efforts in the UK and Europe to bring Remdesivir – the first Covid treatment – to market. His work at Gilead also encompassed antifungals, HDV, and CAR-T cell therapy.
